Provided herein are methods and related compositions for administering viral transfer vectors and antigen-presenting cell targeted immunosuppressants.

The invention provides improved compositions for adoptive T cell therapies for B cell related conditions.

The present invention is related to a dual promoter lentiviral vector and methods of use for the treatment of diseases and disorders, specifically lysosomal storage disorders.

The present invention relates to peptides and compositions for use in improving transduction efficiency of viruses into target cells.

Provided herein are reference guide nucleic acid scaffolds and variants of reference guide nucleic acid scaffolds capable of binding one or more engineered proteins comprising a RuvC cleavage domain. In some embodiments, the variants of the reference guide nucleic acid scaffolds comprise at least one modification compared to the reference guide nucleic acid scaffold sequences and exhibit one or more improved characteristics compared to the reference guide nucleic acid scaffolds.

The present invention provides a lentiviral vector genome comprising at least one modified viral cis-acting sequence, wherein at least one internal open reading frame (ORF) in the viral cis-acting sequence is disrupted.

Provided are a preparation method of trophoblasts with limited generations, a culture method of SNK cells and a method for treating tumor. The preparation method of trophoblasts includes the following steps: ligating a TAX2 gene to a lentiviral expression vector, followed by transferring into competent cells to obtain a lentivirus containing the TAX2 gene; infecting PBMCs with the lentivirus containing the TAX2 gene and culturing, and collecting CD3-cells; ligating a 41BBL-MICA fusion gene to the lentiviral expression vector, followed by transferring into the competent cells to obtain a lentivirus containing the 41BBL-MICA fusion gene; and mixing the CD3-cells with the lentivirus containing the 41BBL-MICA fusion gene and culturing to obtain the trophoblasts with limited generations.

Disclosed herein are cells including pluripotent stem cells that conditionally express an immunosuppressive factor and related methods of their use and generation. In some embodiments, the cells disclosed do not express MHC I and MHC II human leukocyte antigens, and in some cases, also do not express one or more TCR complexes. In some embodiments, hypoimmunogenicity of the cells is controlled by activation of a controllable expression system upon contacting the cells with a specific factor or agent.

The present disclosure provides improved CD33 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

Provided herein are CD25 chimeric antigen receptors and compositions and methods for using the same. Methods for using CD25 chimeric antigen receptors provided herein include, for example, methods of treatment, methods of enhancing the immune system in a subject, and methods of killing a target cell or a population of target cells.